Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTIID)
Date:9/19/2007

Q4/07 Review Issued by Scimitar Equity Research, Inc.

BOSTON, Sept. 19 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTIID), entitled, "The Secret of Success is Constancy of Purpose: VIPRINEX(TM) Could Restore Stroke Patients to Fuller Lives and They Will Be the Real Miracle of NTII's Achievement".

This review is available at our website: http://www.scimitarequity.com.

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTIID is focused on therapies for neurological conditions that occur in connection with ischemic stroke, brain cancer, Alzheimer's disease and dementia. NTIID's strategy is to in-license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTIID's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. For further information, please visit NTII's website at http://www.ntii.com.

NTII's common stock will trade under the symbol "NTIID" for 20 trading days to denote the recent reverse (7 for 1) split. After that time, the symbol will revert back to "NTII". Holders of record will be receiving instructions from NTII's transfer agent to define the procedures of surrendering their pre-split share certificates as well as assign their receipt of the new post-split certificates. NTIID's primary objective in authorizing the reverse split is to raise the share trading price of its common stock and to increase the number of shares of authorized but un-issued common stock.

Scimitar Equity Research, Inc. provides sponsored equity research of the health sciences industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTIID (Nasdaq) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity Research, Inc.

Henry W. McCusker

Director of Research

phone: (617) 559.1080

fax: (617) 559.1083

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
(Date:10/9/2017)... FL (PRWEB) , ... October 09, 2017 , ... The ... scheduled to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... industry is faced with the challenge of how to continue to feed a growing ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):